GRI (GRI Bio Corp) רווח נקי למניה (EPS TTM)

GRI Bio, Inc. (GRI) is developing innovative NKT therapy to combat chronic inflammation. The annual EPS (TTM) growth statistics visualize profit dynamics, where the metric level stands at 93.00. The company's technological foundation enables the seamless scaling of new formulas. However, the lack of stable revenue and the dependence of share prices on clinical trial outcomes create significant financial risks for investors.

Comparing profit dynamics across assets allows an investor to assess the efficiency of capital management. This metric compares the total net earnings per share over the last four quarters with the same period last year. For GRI Bio, Inc. (GRI), this reflects financial stability during the expansion of clinical trials for the GRI-0621 drug. Growth in this indicator confirms the successful monetization of the NKT inhibitor pipeline. By analyzing the 12-month history of YoY EPS changes, one can identify risks of margin compression.